Registry-based analysis of Icatibant and C1-inhibitor use in
treatment of laryngeal attacks of hereditary angioedema

J 2022

Registry-based analysis of Icatibant and C1-inhibitor use in treatment of laryngeal attacks of hereditary angioedema

HAKL, Roman, Pavel KUKLÍNEK, Marta SOBOTKOVA, Irena KRCMOVA, Pavlina KRALICKOVA et. al.

Základní údaje

Originální název

Registry-based analysis of Icatibant and C1-inhibitor use in treatment of laryngeal attacks of hereditary angioedema

Autoři

HAKL, Roman (203 Česká republika, domácí), Pavel KUKLÍNEK (203 Česká republika), Marta SOBOTKOVA (203 Česká republika), Irena KRCMOVA (203 Česká republika), Pavlina KRALICKOVA (203 Česká republika), Martina VACHOVA (203 Česká republika), Jana HANZLIKOVA (203 Česká republika), Martina NOVACKOVA (203 Česká republika), Michal SVOBODA (203 Česká republika), Ingrid KOVÁČOVÁ (703 Slovensko) a Jiří LITZMAN (203 Česká republika, garant, domácí)

Vydání

CLINICAL AND EXPERIMENTAL ALLERGY, HOBOKEN, WILEY, 2022, 0954-7894

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30102 Immunology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.100

Kód RIV

RIV/00216224:14110/22:00126581

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1111/cea.14182

UT WoS

000810252200001

Klíčová slova anglicky

Icatibant; C1-inhibitor; hereditary angioedema; laryngeal attacks

Štítky

14110114, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 5. 9. 2022 12:37, Mgr. Tereza Miškechová

Anotace

V originále

Hereditary angioedema (HAE) is a rare condition which manifests as repeated episodes of localized subcutaneous or submucosal oedema. Oedemas involving the upper airways carry the risk of asphyxiation and death. The aim of this study was to present our clinical experience of icatibant and C1 inhibitor use for treating HAE-1/2 laryngeal attacks (LA). To our knowledge, this is the first direct comparison of these treatment approaches for LA.

Citovat

HAKL, Roman, Pavel KUKLÍNEK, Marta SOBOTKOVA, Irena KRCMOVA, Pavlina KRALICKOVA, Martina VACHOVA, Jana HANZLIKOVA, Martina NOVACKOVA, Michal SVOBODA, Ingrid KOVÁČOVÁ a Jiří LITZMAN. Registry-based analysis of Icatibant and C1-inhibitor use in treatment of laryngeal attacks of hereditary angioedema. CLINICAL AND EXPERIMENTAL ALLERGY. HOBOKEN: WILEY, 2022, roč. 52, č. 8, s. 994-997. ISSN 0954-7894. Dostupné z: https://dx.doi.org/10.1111/cea.14182.

@article{2215440,
   author = {Hakl, Roman and Kuklínek, Pavel and Sobotkova, Marta and Krcmova, Irena and Kralickova, Pavlina and Vachova, Martina and Hanzlikova, Jana and Novackova, Martina and Svoboda, Michal and Kováčová, Ingrid and Litzman, Jiří},
   article_location = {HOBOKEN},
   article_number = {8},
   doi = {http://dx.doi.org/10.1111/cea.14182},
   keywords = {Icatibant; C1-inhibitor; hereditary angioedema; laryngeal attacks},
   language = {eng},
   issn = {0954-7894},
   journal = {CLINICAL AND EXPERIMENTAL ALLERGY},
   title = {Registry-based analysis of Icatibant and C1-inhibitor use in treatment of laryngeal attacks of hereditary angioedema},
   url = {https://onlinelibrary.wiley.com/doi/10.1111/cea.14182},
   volume = {52},
   year = {2022}
}

TY  - JOUR
ID  - 2215440
AU  - Hakl, Roman - Kuklínek, Pavel - Sobotkova, Marta - Krcmova, Irena - Kralickova, Pavlina - Vachova, Martina - Hanzlikova, Jana - Novackova, Martina - Svoboda, Michal - Kováčová, Ingrid - Litzman, Jiří
PY  - 2022
TI  - Registry-based analysis of Icatibant and C1-inhibitor use in treatment of laryngeal attacks of hereditary angioedema
JF  - CLINICAL AND EXPERIMENTAL ALLERGY
VL  - 52
IS  - 8
SP  - 994-997
EP  - 994-997
PB  - WILEY
SN  - 09547894
KW  - Icatibant
KW  - C1-inhibitor
KW  - hereditary angioedema
KW  - laryngeal attacks
UR  - https://onlinelibrary.wiley.com/doi/10.1111/cea.14182
N2  - Hereditary angioedema (HAE) is a rare condition which manifests as repeated episodes of localized subcutaneous or submucosal oedema. Oedemas involving the upper airways carry the risk of asphyxiation and death. The aim of this study was to present our clinical experience of icatibant and C1 inhibitor use for treating HAE-1/2 laryngeal attacks (LA). To our knowledge, this is the first direct comparison of these treatment approaches for LA.
ER  -

HAKL, Roman, Pavel KUKLÍNEK, Marta SOBOTKOVA, Irena KRCMOVA, Pavlina KRALICKOVA, Martina VACHOVA, Jana HANZLIKOVA, Martina NOVACKOVA, Michal SVOBODA, Ingrid KOVÁČOVÁ a Jiří LITZMAN. Registry-based analysis of Icatibant and C1-inhibitor use in treatment of laryngeal attacks of hereditary angioedema. \textit{CLINICAL AND EXPERIMENTAL ALLERGY}. HOBOKEN: WILEY, 2022, roč.~52, č.~8, s.~994-997. ISSN~0954-7894. Dostupné z: https://dx.doi.org/10.1111/cea.14182.

Podrobný výpis o publikaci